July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase
Omega reveals venture tally
Omega Therapeutics Inc. announced it has raised $85 million since its 2016 launch by Flagship Pioneering to support development of therapies targeting chromatin structures. The funding includes a series A round from Flagship and a series B round led by the firm with participation by other investors. Other investors and details on the rounds were not disclosed.
Eventide leads Praxis’ $110M round
Praxis Precision Medicines Inc. raised $110 million in a series C1 round led by Eventide Asset Management, bringing its venture funding raised to more than $211 million. Existing investors Vida Ventures, Novo Holdings, Blackstone Life Sciences and OCV Partners also participated in the round, along with new investors Avoro Capital Advisors, Surveyor Capital, Point72, Cormorant Asset Management, Qatar Investment Authority, Irving Investors, Adage Capital Management, Verition Fund Management and Ample Plus Fund. The company has three neurology programs in the clinic (see “Connecting the Neurological Dots”).
Megaround for RuiPing Dong’s HaiHe ...